SXTP (60 Degrees Pharmaceuticals) FFO


SXTP 60 Degrees Pharmaceuticals Inc SXTP
44 GF Score
Price $1.69
GF Value $2.07
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is 60 Degrees Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

SXTP
44GF Score
60 Degrees Pharmaceuticals Inc SXTP
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is 60 Degrees Pharmaceuticals (SXTP) Overvalued in 2026?

Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals stock appears to be undervalued. The current stock price of $1.69 is trading 18.4% below its estimated GF Value™ of $2.07. GuruFocus considers 60 Degrees Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for SXTP:

  • FFO:
  • GF Value™: $2.07 vs. price of $1.69 (18.4% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the SXTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

60 Degrees Pharmaceuticals Business Description

Address 1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
44GF Score

Get the complete analysis for SXTP

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.69
Price
$2.07
GF Value